<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>My HTML Page</title>
  <link rel="stylesheet" type="text/css" title="Cool stylesheet" href="style.css">
</head>
<body>
  <div class="main" id="main-doc">

    <!-- Section 1-->
    <section class="main-section" id="ummary">
      <header >
        Summary of Recent Changes and Updates
      </header>
      Webpage content and individual PDFs are updated when there’s new guidance concerning the Moderna COVID-19 vaccine. Expand each section below to see a summary of new and updated items spanning the past month.
      <br />
      Updates on 8/23/2021
      <br />
      Moderna materials have been updated to include the updated Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Authorized in the United States posted on August 13, 2021.
      Updates on 5/15/2021
      <br />
      Moderna materials have been updated to include the Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Authorized in the United States from May 14, 2021.

    </section>
    <!-- End of Section 1-->



    <!-- Section 2-->
    <section class="main-section" id="general_information">
      <header>
        General Vaccine Information
      </header>

      Vaccine: Moderna COVID-19 Vaccine
      Multidose vial: maximum of 15 doses per vial
      <br />
      Dosage: 0.5 mL
      <br />
      Do NOT mix with a diluent.
      <br />
      Discard vial when there is not enough vaccine to obtain a complete dose. Do NOT combine residual vaccine from multiple vials to obtain a dose.
      <br />
      18 years of age and older
      <br />
      2-dose series separated by 28 days*
      <br />
      A series started with COVID-19 vaccine (Moderna) should be completed with this product.
      <br />
      * Moderately to severely immunocompromised people:  Consider an additional dose at least 28 days after the initial 2-dose primary series.
      <br />
      Intramuscular (IM) injection in the deltoid muscle
    </section>
    <!-- End of Section 2-->



    <!-- Section 3-->
    <section class="main-section" id="administration">
      <header>
        Administration Overview
      </header>
      Before administering vaccine, screen recipients for contraindications and precautions, even if the recipient is scheduled to receive the second dose. The recipient’s health condition or recommendations regarding contraindications and precautions for vaccination may change from one visit to the next.
      <br />
      To assess patients correctly and consistently, vaccination providers should use a standardized, comprehensive screening tool.

    </section>
    <!-- End of Section 3-->


    <!-- Section 4-->
    <section class="main-section" id="storage">
      <header>
        Storage and Handling Overview
      </header>
      <ul>
        <li>
          Vaccine will arrive frozen between -50°C and -15°C (-58°F and 5°F).
        </li>
        <li>
          An ancillary supply kit will arrive separately from the vaccine.
        </li>
        <li>
          Unpack the vaccine shipment following the manufacturer’s directions.
        </li>
      </ul>




    </section>
    <!-- End of Section 4 -->



    <!-- Section 5-->
    <section class="main-section" id="documentation">
      <header>
        Document the Vaccination
      </header>
      <p>

        COVID-19 vaccination providers must document vaccine administration in their medical record systems within 24 hours of administration and use their best efforts to report administration data to the relevant system for the jurisdiction (i.e., immunization information system) as soon as practicable and no later than 72 hours after administration.

      </p>
    </section>
    <!-- End of Section 1-->

  </div>
  <script src="main.js" type="text/javascript"></script>
</body>
</html>
